Zhongshan Institute for Drug Discovery has divulged new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of cancer, neurodegeneration, malaria, AIDS, gout, diabetes, renal failure and cardiovascular disorders, among others.

Architect Therapeutics Inc. has identified new spiro heterocyclic cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer, myeloproliferative, autoimmune disease, inflammatory disorder, viral infections and fibrosis.

Universitätsklinikum Hamburg-Eppendorf has synthesized new transient receptor potential cation channel subfamily M member 4 (TRPM4) antagonists potentially useful for the treatment of neurodegeneration, multiple sclerosis and inflammatory disorders.

Guardian Biosciences LLC has discovered new D-β-hydroxybutyrate compounds potentially useful for the treatment of traumatic brain injury (TBI).

Tango Therapeutics Inc. has disclosed new HBS1-like protein (HBS1L; HBS1) degradation inducers potentially useful for the treatment of cancer.

Yantai Rongchang Pharmaceutical Co. Ltd. has synthesized new GTPase KRAS mutant inhibitors potentially useful for the treatment of pancreatic cancer.

The University of Hong Kong has patented new transcription antitermination protein NusB/N-utilization substance E (NusE) interaction inhibitors reported to be useful for the treatment of gram-positive or gram-negative bacterial infections and fungal infections.

Boyuan Pharmaceutical (Suzhou) Co. Ltd. has disclosed new herpes simplex virus (HSV) inhibitors potentially useful for the treatment of HSV infection and dementia.

Work at Shanghai Jeyou Pharmaceutical Co. Ltd. has led to the identification of new thioether-substituted galactopyranoside derivatives acting as galectin-3 (LGALS3) inhibitors.

Hefei Shengpu Pharmaceutical Technology Co. Ltd. has divulged new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer.